Has COVID-19 changed the future of pharmaceutical regulation?07 Oct 2021
Available for free
Has COVID-19 revolutionizedthe future of regulation of medicine development and authorization or are we simply responding to an unprecedented global pandemic? Our Head of Regulatory Affairs and Enhanced Services, Harriet Edwards, delves deep on how the pademic changed the industry we work in today.
COVID-19, or SARS-CoV-2, has undoubtedly changed the world as we know it, affecting daily life, health, and economics to an unprecedenteddegree. Due to the widespread and devastating impact of this previously unknown virus, there has been a massive effort from the pharmaceuticalindustry to rapidly develop a vaccine to protect the population. As a consequence of the increasingly evolving threat of COVID-19, developersand regulators have had to respond accordingly, learning about the virus while attempting to develop and regulate treatments concurrently
This article aims to examine whether COVID-19 (SARS-CoV-2) has changed the future of regulation through identifying and discussingthe notable regulatory milestones achieved over the course of the COVID-19 pandemic (to date), and critically analyzing the regulation of thosesuccessful vaccine candidates that have been authorized at the time of writing, while posing the ultimate question; has COVID-19 revolutionizedthe future of regulation of medicine development and authorization or are we simply responding to an unprecedented global pandemic?
Visit our scientific library to access the full article: Has COVID-19 changed the future of pharmaceutical regulation?